In this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode:
1. Risk stratification of PMF:
MIPSS70 Score: http://www.mipss70score.it
https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886
Genetically inspired prognostic scoring system (GIPSS):
https://www.nature.com/articles/s41375-018-0107-z
Type 1 CALR mutation:
https://ashpublications.org/blood/article/124/15/2465/33454
MYSEC-PM:
http://www.mysec-pm.eu
https://www.nature.com/articles/leu2017169
2. Treatment of PMF with JAK inhibitors
https://pubmed.ncbi.nlm.nih.gov/36680511/
Momelotinib:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02036-0/fulltext
Pacritinib : https://ashpublications.org/blood/article/140/Supplement%201/1518/490663
https://jamanetwork.com/journals/jamaoncology/fullarticle/2674384
Fedratinib:
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18284
3. Allogeneic Transplant in PMF
https://ashpublications.org/hematology/article/2021/1/453/482995
Black African-American patients with primary myelofibrosis
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022009611/494460
4. Imtelestat in PMF
https://www.nejm.org/doi/full/10.1056/NEJMoa1310523
What is Blood Cancer Talks?
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk